Topic:
Clinical Trials
Latest Headlines
Latest Headlines
AbbVie spins out a PhII orphan drug to Receptos--with a hook attached
San Diego-based Receptos has snagged a deal to put one of AbbVie's respiratory drugs through a Phase II study, taking on the risk of mid-stage work while securing an option deal that allows AbbVie the right to step back in if the therapy looks promising enough to take it forward into Phase III.
Analysts cheer decision to continue Merck's controversial Vytorin study
The huge late-stage study that is seeking to determine once and for all if Merck's combo cholesterol drug Vytorin actually works and is safe will run its full course now that an independent safety board has signed off following a review of the data.
Leading industry backlash, AbbVie counterattacks against move to unlock Humira data
GlaxoSmithKline's move to rehabilitate its reputation with a commitment to open up its data vault on approved drugs has won widespread acclaim, and at least limited support from Roche. Read more >>
Roche touts upbeat PhII results for heart drug
Roche is reporting encouraging results from a mid-stage study of inclacumab, saying the data demonstrated a clear clinical benefit by reducing inflammation during angioplasty.
Aeterna craters after researchers slam brakes on another failed perifosine PhIII
Canada's Aeterna Zentaris took another bad hit today after it announced that it is scuttling a Phase III study of perifosine for relapsed/refractory multiple myeloma. The move came after the drug safety monitoring board decided that there was little to no chance the therapy would meet the hurdle for progression free survival.
Report: Only 45 Indian trial deaths compensated since 2005
As many as 2,868 people have died in Indian clinical trials over the past 7 years, and sponsors and CROs have paid out compensation in just 45 of those instances, according to India's Business Standard .
Medicines Co.'s blood thinner finally reaps positive results in third PhIII
If at first you don't succeed in Phase III, try, try again. Only enroll lots more patients and improve the trial design. That was The Medicines Company's strategy when it opted to pay for a third pivotal study of the blood thinner cangrelor.
Novartis encouraged by typhoid vaccine progress
Novartis has talked up the prospects of its typhoid vaccine candidate after completing Phase II safety studies. A wider rollout is now being considered as Novartis pushes to develop a vaccine to eliminate a disease that still kills 200,000 people a year.
J&J, Gilead combo quells hep C in 100% of PhII cohort
Medivir has posted a stellar snapshot of interim data from its Phase IIa study of a combo hep C treatment that adds Gilead's hot property--GS-7977--with the Swedish biotech's simeprevir (TMC435), which is partnered with Johnson & Johnson.
Covance allies with M2Gen for personalized medicine, cancer trials
Covance is stepping up its personalized medicine services, teaming up with the biomarker-focused M2Gen to better identify ideal patients for oncology drug trials.
